Charities Send Joint Letter to Biogen

16 May 2018

Today, we have written to leading managers of Biogen about the Scottish Medicines Consortium’s decision that due to pricing, nusinersen may only be accessed by those with SMA Type 1. We are urging Biogen to continue their firm commitment to the SMA community, review their pricing and resubmit their application with the aim of access being extended to those with SMA Types 2 and 3. 

Read the letter